[go: up one dir, main page]

MX2019003241A - Moleculas de union que modulan una actividad biologica expresada por una celula. - Google Patents

Moleculas de union que modulan una actividad biologica expresada por una celula.

Info

Publication number
MX2019003241A
MX2019003241A MX2019003241A MX2019003241A MX2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A MX 2019003241 A MX2019003241 A MX 2019003241A
Authority
MX
Mexico
Prior art keywords
cell
modulate
biological activity
activity expressed
molecules
Prior art date
Application number
MX2019003241A
Other languages
English (en)
Inventor
Throsby Mark
Anna Wilhelmina Geuijen Cecilia
Adriaan De Kruif Cornelis
Logtenberg Ton
Klooster Rinse
Johannes Tacken Paulus
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2019003241A publication Critical patent/MX2019003241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona medios y métodos para estimular la actividad de un miembro de la superfamilia de receptores del TNF en una célula. La invención proporciona, además, moléculas de unión tales como anticuerpos que comprenden al menos dos parátopos, en donde un primer parátopo puede unir una parte extracelular del miembro y un segundo parátopo puede unir una parte extracelular de una segunda proteína de membrana (diferente).
MX2019003241A 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula. MX2019003241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190499 2016-09-23
PCT/NL2017/050634 WO2018056821A1 (en) 2016-09-23 2017-09-22 Binding molecules that modulate a biological activity expressed by a cell

Publications (1)

Publication Number Publication Date
MX2019003241A true MX2019003241A (es) 2019-11-12

Family

ID=57132987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003241A MX2019003241A (es) 2016-09-23 2017-09-22 Moleculas de union que modulan una actividad biologica expresada por una celula.

Country Status (19)

Country Link
US (2) US11685786B2 (es)
EP (2) EP4342912A3 (es)
JP (2) JP7305538B2 (es)
KR (2) KR20190065318A (es)
CN (2) CN117510643A (es)
AU (3) AU2017332452B2 (es)
BR (1) BR112019005895A2 (es)
CA (1) CA3038020A1 (es)
EA (1) EA201990578A1 (es)
ES (1) ES2981272T3 (es)
IL (2) IL311603A (es)
MA (1) MA46278A (es)
MX (1) MX2019003241A (es)
NZ (1) NZ751956A (es)
PH (1) PH12019550044A1 (es)
TW (1) TWI879715B (es)
UA (1) UA127449C2 (es)
WO (1) WO2018056821A1 (es)
ZA (1) ZA201902146B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
MX2018016320A (es) 2016-06-20 2019-05-30 F Star Delta Ltd Moleculas de union que se unen a (pd-l1) y (lag-3).
KR20240017129A (ko) 2016-07-14 2024-02-06 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2018156740A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EP3609921A2 (en) 2017-04-13 2020-02-19 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
EP3649156A1 (en) 2017-07-06 2020-05-13 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
WO2019025545A1 (en) 2017-08-04 2019-02-07 Genmab A/S BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
AU2018387741A1 (en) 2017-12-19 2020-07-23 Invox Pharma Limited FC binding fragments comprising a PD-L1 antigen-binding site
KR20200136473A (ko) 2018-03-30 2020-12-07 유레카 쎄라퓨틱스, 인코포레이티드 Cd22를 표적으로 하는 구축물 및 이의 용도
KR20200139189A (ko) 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
EP3778635A4 (en) * 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. ANTI-PD-L1 ANTIBODIES AND ITS USE
JP7332194B2 (ja) * 2018-06-29 2023-08-23 スーチョウ スマートヌクライド バイオファーマシューティカル カンパニー リミテッド Ｐｄ－ｌ１結合ポリペプチドおよびそれらの使用
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
TWI861005B (zh) * 2018-07-12 2024-11-11 英商英沃克斯製藥有限公司 結合pd-l1及cd137的抗體分子
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
TWI847989B (zh) 2018-07-12 2024-07-11 英商Ｆ—星治療有限公司 結合cd137及ox40的抗體分子
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
EP3636320A1 (en) * 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) * 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
AU2019375014A1 (en) * 2018-11-06 2021-05-27 BioNTech SE Antibody formulation
WO2020231809A1 (en) * 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Humanized anti-cd137 antibodies and uses thereof
US11725058B2 (en) 2019-06-26 2023-08-15 Ap Biosciences, Inc. CD137 antibodies for T-cell activation
CN114555638B (zh) * 2019-10-11 2023-08-22 南京维立志博生物科技有限公司 结合4-1bb的抗体及其用途
IL294967A (en) * 2020-02-04 2022-09-01 Genmab As Antibodies for use in therapy
AU2021224787A1 (en) * 2020-02-21 2022-10-06 Macrogenics, Inc. CD137 binding molecules and uses thereof
WO2021222074A1 (en) * 2020-04-28 2021-11-04 Ohio University Methods for extending the shelf-life of stored donor blood and/or red blood cells and treated red blood cell compositions produced thereby
WO2021235936A1 (en) 2020-05-21 2021-11-25 Merus N.V. Methods and means for the production of ig-like molecules
CA3190649A1 (en) * 2020-07-31 2022-02-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
AU2021398976A1 (en) 2020-12-16 2023-07-06 Merus N.V. Multispecific antibodies for the treatment of cancer
AU2022206035A1 (en) * 2021-01-08 2023-07-20 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
MX2023011362A (es) 2021-03-31 2023-10-05 Merus Nv Anticuerpos multiespecificos novedosos.
CN119868536A (zh) 2022-01-25 2025-04-25 美勒斯公司 用于治疗癌症的组合疗法
AU2023271827A1 (en) * 2022-05-18 2024-12-05 Regeneron Pharmaceuticals, Inc. Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
EP1975182A1 (en) * 2000-02-01 2008-10-01 PanGenetics B.V. CD40-binding APC-activating molecules
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006091209A2 (en) * 2005-02-23 2006-08-31 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SI2147594T1 (sl) 2008-06-27 2014-02-28 Merus B.V. Protitelo proizvajajoči ne-humani sesalci
MY188826A (en) 2008-12-09 2022-01-06 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
US10590195B2 (en) 2010-06-25 2020-03-17 Vaccibody As Homodimeric protein constructs
KR101527297B1 (ko) 2010-09-09 2015-06-26 화이자 인코포레이티드 4-1ｂｂ 결합 분자
PL2838917T3 (pl) 2012-04-20 2019-12-31 Merus N.V. Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do Ig
WO2014116846A2 (en) * 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
SG10201909806SA (en) * 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
EP3083687A2 (en) 2013-12-17 2016-10-26 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3686219A1 (en) 2014-02-04 2020-07-29 Pfizer Inc Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
PL3130606T3 (pl) 2014-04-07 2022-02-07 Chugai Seiyaku Kabushiki Kaisha Przeciwciała dwuswoiste aktywujące układ odpornościowy
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
HRP20220811T1 (hr) 2015-01-08 2022-09-30 BioNTech SE Agonistička sredstva za vezanje tnf receptora
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3268037B1 (en) * 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
CN107709364A (zh) 2015-04-07 2018-02-16 豪夫迈·罗氏有限公司 具有激动剂活性的抗原结合复合体及使用方法
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
WO2017060144A1 (en) * 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies with tetravalency for a costimulatory tnf receptor
MX2018006477A (es) * 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
EP3402507A4 (en) 2016-01-11 2019-08-07 Inhibrx, Inc. MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS
US10501551B2 (en) * 2016-01-11 2019-12-10 Inhibrx, Inc. Multivalent and multispecific 41BB-binding fusion proteins
ES2910365T3 (es) * 2016-04-22 2022-05-12 Alligator Bioscience Ab Nuevos polipéptidos biespecíficos contra CD137
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
SG11201810591VA (en) 2016-05-27 2018-12-28 Abbvie Biotherapeutics Inc Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
KR20250007013A (ko) 2025-01-13
AU2017332452B2 (en) 2021-01-07
AU2021202085A1 (en) 2021-04-29
EP4342912A2 (en) 2024-03-27
UA127449C2 (uk) 2023-08-30
IL311603A (en) 2024-05-01
AU2017332452A1 (en) 2019-04-11
IL265541B1 (en) 2024-04-01
CA3038020A1 (en) 2018-03-29
BR112019005895A2 (pt) 2019-06-11
EA201990578A1 (ru) 2019-10-31
EP4342912A3 (en) 2024-05-22
KR20190065318A (ko) 2019-06-11
US11685786B2 (en) 2023-06-27
CN117510643A (zh) 2024-02-06
PH12019550044A1 (en) 2019-11-11
JP2019537429A (ja) 2019-12-26
AU2024220074A1 (en) 2024-10-17
JP7305538B2 (ja) 2023-07-10
EP3515951A1 (en) 2019-07-31
NZ751956A (en) 2022-01-28
US20240209105A1 (en) 2024-06-27
ZA201902146B (en) 2024-08-28
WO2018056821A8 (en) 2019-05-02
ES2981272T3 (es) 2024-10-08
AU2021202085B2 (en) 2024-07-11
IL265541A (en) 2019-05-30
TWI879715B (zh) 2025-04-11
CN109983033A (zh) 2019-07-05
IL265541B2 (en) 2024-08-01
MA46278A (fr) 2019-07-31
US20200017595A1 (en) 2020-01-16
EP3515951B1 (en) 2024-02-28
TW201920653A (zh) 2019-06-01
CN109983033B (zh) 2023-10-31
WO2018056821A1 (en) 2018-03-29
JP2023116811A (ja) 2023-08-22

Similar Documents

Publication Publication Date Title
MX2019003241A (es) Moleculas de union que modulan una actividad biologica expresada por una celula.
PH12018500636A1 (en) Bispecific antibodies specific for a costimulatory tnf receptor
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
JOP20210076A1 (ar) تركيبات أجسام مضادة ثنائية الاختصاص لربط خلايا تائية
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
EA202192165A1 (ru) Иммуноглобулины, связывающие человеческие v9v2 т-клеточные рецепторы
MX389547B (es) Moleculas de union que inhibe el crecimiento de cancer.
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
MX2018008308A (es) Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
MX385545B (es) Anticuerpos humanos para pd-1.
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
EA201891066A1 (ru) Антитела к ror1
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
BR112020000209A8 (pt) moléculas de ligação que modulam uma atividade biológica expressa por uma célula
EA201892440A1 (ru) Антитела к tl1a и их применения
MX380702B (es) Proteinas de union al antigeno del receptor de oncostatina m.
TN2019000188A1 (en) Gremlin-1 crystal structure and inhibitory antibody
EA201790314A1 (ru) Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор
MX2022009146A (es) Control cuantitativo de la actividad de celulas dise?adas que expresan inmuno-receptores universales.
BR112016024742A2 (pt) método para a seleção de uma proteína, proteínas de ligação ao antígeno, anticorpos, imunoconjugado, formulação farmacêutica, uso do anticorpo, ácido nucleico e polipeptídeo
EA201990543A1 (ru) Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?